Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ECMO breakthrough? major trial aims to cut deadly complications

NCT ID NCT06526533

Knowledge-focused Sponsor: Australian and New Zealand Intensive Care Research Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing different treatments to reduce major complications and improve survival in 600 adults who need ECMO—a machine that does the work of the heart and lungs. Researchers will compare how well these treatments work in the first 28 days. The goal is to find safer, more effective ways to care for critically ill patients on ECMO.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PLATFORM INCLUSION CRITERIA: * Patients receiving ECMO * Patients enrolled in the EXCEL Registry - NCT03793257 PLATFORM EXCLUSION CRITERIA: * Treating clinician regards death as imminent and inevitable * Treating clinician determines it is not in the patient's best interests RBC TRANSFUSION DOMAIN INCLUSION CRITERIA: • Aged 18 years or older RBC TRANSFUSION DOMAIN EXCLUSION CRITERIA: * Contraindication to RBC transfusion (including known patient preference) * Limitations of care put in place either through patient wishes or the treating medical teams. * Participant has already received ECMO \>12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery) * The treating physician anticipates that ECMO treatment will cease before the end of tomorrow * The treating physician deems the study is not in the patient's best interest * The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds * Actively listed for a solid organ transplant and has not yet received one * Suspected or confirmed to be pregnant * Previous ECMO treatment during the same hospital admission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (acute respiratory distress syndrome) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome cardiac arrest Critical Illness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS (acute respiratory distress syndrome) Cardiac arrest (CA) Critical illness Extracorporeal membrane oxygenation complication Intensive care medicine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Prince Alfred Hospital

    NOT_YET_RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • St. Vincent's Hospital Sydney

    RECRUITING

    Sydney, New South Wales, 2010, Australia

  • The Alfred Hospital

    NOT_YET_RECRUITING

    Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.